Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits

International Journal of Cardiology

Volumn 62, Issue 3, 1997, Pages 181-190

  Ohno, Yoshitsugu ^a   Minatoguchi, Shinya ^a   Uno, Yoshihiro ^a   Kariya, Tatsuya ^a   Arai, Masazumi ^a   Yamashita, Kazuya ^a   Fujiwara, Takako ^b   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

Author keywords

Infarct size; K(ATP) channel; Nicorandil; Plasma nicorandil concentration; Rabbit

Indexed keywords

ACTIN; GLIBENCLAMIDE; NICORANDIL; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; HEART RATE; LINEAR MODELS; MALE; MYOCARDIAL INFARCTION; NIACINAMIDE; NICORANDIL; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RABBITS; TIME FACTORS; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION;

EID: 0031578784     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00270-2     Document Type: Article

References (16)

1. + channels. Trends Pharmacol Sci. 10:1989;431-434.
2. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther. 4:1990;1075-1088.
3. Lamping K.A., Gross G.J. Comparative effects of a new nicotinamide nitrate derivative, nicorandil (SG-75), with nifedipine and nitroglycerin on true collateral blood flow following acute coronary occlusion in dogs. J Cardiovasc Pharmacol. 6:1984;601-608.
4. + channel opening property and nitrate property. Clin Exp Pharmacol Physiol. 20:1993;595-602.
5. Lamping K.A., Christensen C.W., Pelc L.R., Warltier D.C., Gross G.J. Effects of nicorandil and nifedipine on protection of ischemic myocardium. J Cardiovasc Pharmacol. 6:1984;536-542.
6. Endo T., Nejima J., Kiuchi K.et al. Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs. J Cardiovasc Pharmacol. 12:1988;587-592.
7. Gross G.J., Auchamoach J.A., Maruyama M., Warltier D.C., Pieper G.M. Cardioprotective effects on nicorandil. J Cardiovasc Pharmacol. 20(Suppl. 3):1992;S22-S28.
8. Maxwell M.P., Hearse D.J., Jellon D.M. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 21:1987;737-746.
9. Tanikawa M., Uzu M., Ohsawa Y., Fukushima M. Sensitive method for determination of nicorandil in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 617:1993;163-167.
10. Grover G.J., Sleph P.G., Parham C.S. Nicorandil improves postischemic contractile function independently of direct myocardial effects. J Cardiovasc Pharmacol. 15:1990;698-705.
11. Auchampach J.A., Cavero I., Gross G.J. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol. 20:1992;765-771.
12. Warltier D.C., Auchampach J.A., Gross G.J. Relationship of severity of myocardial stunning to ATP dependent potassium channel modulation. J Card Surg. 8(Suppl):1993;279-283.
13. Gross G.J., Auchampach J.A. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 70:1992;223-233.
14. Toombs C.F., Moore T.L., Shebuski R.J. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 27:1993;617-622.
15. Gross G.J., Auchampach J.A. Antiischemic actions of potassium channel openers in experimental myocardial ischaemia/reperfusion injury in dogs. Eur Heart J. 14(Suppl. B):1993;10-15.
16. ++ entry in rabbit aorta. J Pharmacol Exp Ther. 233:1985;100-111.